The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Transcriptional Activation of Apolipoprotein CIII Expression by Glucose May Contribute to Diabetic Dyslipidemia
Abstract
Objective—: Hypertriglyceridemia and fatty liver are common in patients with type 2 diabetes, but the factors connecting alterations in glucose metabolism with plasma and liver lipid metabolism remain unclear. Apolipoprotein CIII (apoCIII), a regulator of hepatic and plasma triglyceride metabolism, is elevated in type 2 diabetes. In this study, we analyzed whether apoCIII is affected by altered glucose metabolism. Methods and Results—: Liver-specific insulin receptor–deficient mice display lower hepatic apoCIII mRNA levels than controls, suggesting that factors other than insulin regulate apoCIII in vivo. Glucose induces apoCIII transcription in primary rat hepatocytes and immortalized human hepatocytes via a mechanism involving the transcription factors carbohydrate response element–binding protein and hepatocyte nuclear factor-4α. ApoCIII induction by glucose is blunted by treatment with agonists of farnesoid X receptor and peroxisome proliferator-activated receptor-α but not liver X receptor, ie, nuclear receptors controlling triglyceride metabolism. Moreover, in obese humans, plasma apoCIII protein correlates more closely with plasma fasting glucose and glucose excursion after oral glucose load than with insulin. Conclusion—: Glucose induces apoCIII transcription, which may represent a mechanism linking hyperglycemia, hypertriglyceridemia, and cardiovascular disease in type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408 · cited 1×
“method(1), plated in collagen-coated plates and incubated at 37°C for 4-6h using serum-free”
Adiels, M., Olofsson, S.-O., Taskinen, M.-R., & Borén, J. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.160192 · Cited by 820
Self-citationPollin, T. I., Damcott, C. M., Shen, H., Ott, S. H., Shelton, J., Horenstein, R. B., Post, W., McLenithan, J. C., Bielak, L. F., Peyser, P. A., et al. (2008) · Science · doi:10.1126/science.1161524 · Cited by 688
A glucose-responsive transcription factor that regulates carbohydrate metabolism in the liver
Yamashita, H., Takenoshita, M., Sakurai, M., Bruick, R. K., Henzel, W. J., Shillinglaw, W., Arnot, D., & Uyeda, K. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161284298 · Cited by 682
Hypertriglyceridemia as a Result of Human apo CII Gene Expression in Transgenic Mice
Ito, Y., Azrolan, N., O'Connell, A., Walsh, A., & Breslow, J. L. (1990) · Science · doi:10.1126/science.2167514 · Cited by 539
Sacks, F. M., Alaupovic, P., Moye, L. A., Cole, T. G., Sussex, B., Stampfer, M. J., Pfeffer, M. A., & Braunwald, E. (2000) · Circulation · doi:10.1161/01.cir.102.16.1886 · Cited by 490
Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease
Petersen, K. F., Dufour, S., Hariri, A., Nelson-Williams, C., Foo, J. N., Zhang, X.-M., Dziura, J., Lifton, R. P., & Shulman, G. I. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907295 · Cited by 428
Ginsberg, H. N., Le, N. A., Goldberg, I. J., Gibson, J. C., Rubinstein, A., Wang-Iverson, P., Norum, R., & Brown, W. V. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112713 · Cited by 424
Cohn, J. S., Patterson, B. W., Uffelman, K. D., Davignon, J., & Steiner, G. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032056 · Cited by 170
Mendivil, C. O., Zheng, C., Furtado, J., Lel, J., & Sacks, F. M. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.109.197830 · Cited by 145
Research works printed but not linked: 36
- 10.1021/bi00337a028 · DOI · Paper page
- 10.1016/S0021-9258(17)31559-4 · DOI · Paper page
- 10.1016/S0022-2275(20)32379-8 · DOI · Paper page
- 10.1016/S0022-2275(20)38512-6 · DOI · Paper page
- 10.1016/0026-0495(79)90004-0 · DOI · Paper page
- 10.1016/S0140-6736(79)92068-3 · DOI
- 10.1016/S0022-2275(20)32211-2 · DOI
- 10.1172/JCI111711 · DOI · Paper page
- 10.1074/jbc.272.50.31348 · DOI
- 10.1016/S0022-2275(20)34342-X · DOI · Paper page
- 10.1016/j.diabres.2004.02.020 · DOI
- 10.1016/j.atherosclerosis.2005.10.013 · DOI
- 10.1161/circulationaha.106.622514 · DOI · Paper page
- 10.2337/diacare.27.6.1358 · DOI
- 10.1074/jbc.270.22.13470 · DOI · Paper page
- 10.1016/0021-9150(89)90075-0 · DOI
- 10.1161/atvbaha.108.169383 · DOI
- 10.1172/JCI200419992 · DOI
- 10.1016/S0022-2275(20)39938-7 · DOI · Paper page
- 10.1016/j.tem.2005.10.003 · DOI
- 10.1074/jbc.270.37.21991 · DOI · Paper page
- 10.1073/pnas.0401516101 · DOI · Paper page
- 10.1042/BJ20060659 · DOI
- 10.1074/jbc.M605023200 · DOI · Paper page
- 10.1016/S1097-2765(05)00015-8 · DOI · Paper page
- 10.1046/j.1464-5491.2002.00835.x · DOI · Paper page
- 10.1021/bi981068i · DOI
- 10.1128/MCB.13.12.7725 · DOI
- 10.1038/nature05449 · DOI · Paper page
- 10.1016/S0016-5085(03)00896-5 · DOI · Paper page
- 10.2337/diabetes.54.3.664 · DOI
- 10.1172/JCI118324 · DOI · Paper page
- 10.1093/ajcn/85.6.1527 · DOI
- 10.1074/jbc.M310333200 · DOI
- 10.1074/jbc.M203421200 · DOI
- 10.1152/ajpendo.00157.2006 · DOI
Cited by
Dyslipidemia in obesity: Mechanisms and potential targets
Klop, B., Elte, J., & Cabezas, M. (2013) · Nutrients · doi:10.3390/nu5041218 · Cited by 1,665
“Elevated levels of apo C-III in obesity can be explained by glucose-stimulated transcription of apo C-III and it has been described that plasma apo C-III levels correlate with fasting glucose and glucose excursion after an oral glucose test in obese humans [65].”
BackgroundPawlak, M., Lefebvre, P., & Staels, B. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.10.039 · Cited by 1,578
Self-citationFructose metabolism and metabolic disease
Hannou, S. A., Haslam, D. E., McKeown, N. M., & Herman, M. A. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96702 · Cited by 561
Dysregulated lipid metabolism links NAFLD to cardiovascular disease
Deprince, A., Haas, J. T., & Staels, B. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101092 · Cited by 554
Self-citationWu, L., & Parhofer, K. G. (2014) · Metabolism · doi:10.1016/j.metabol.2014.08.010 · Cited by 516
Graham, M. J., Lee, R. G., Bell, T. A., Fu, W., Mullick, A. E., Alexander, V. J., Singleton, W., Viney, N., Geary, R., Su, J., et al. (2013) · Circulation Research · doi:10.1161/circresaha.111.300367 · Cited by 377
Molecular aspects of fructose metabolism and metabolic disease
Herman, M. A., & Birnbaum, M. J. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.09.010 · Cited by 290
Stanhope, K. L., Medici, V., Bremer, A. A., Lee, V., Lam, H. D., Nunez, M. V., Chen, G. X., Keim, N. L., & Havel, P. J. (2015) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.114.100461 · Cited by 270
The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans
Borén, J., Packard, C. J., & Taskinen, M.-R. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00474 · Cited by 196
“In contrast, glucose stimulates expression of APOC3 via hepatic nuclear factor-4 (HNF4) and carbohydrate-responsive element binding protein (ChREBP) (41).”
BackgroundSelf-citationApolipoprotein C-III: from pathophysiology to pharmacology
Norata, G. D., Tsimikas, S., Pirillo, A., & Catapano, A. L. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.07.001 · Cited by 182
Postprandial hypertriglyceridemia as a coronary risk factor
Borén, J., Matikainen, N., Adiels, M., & Taskinen, M.-R. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.01.015 · Cited by 182
Self-citationDigenio, A., Dunbar, R. L., Alexander, V. J., Hompesch, M., Morrow, L., Lee, R. G., Graham, M. J., Hughes, S. G., Yu, R., Singleton, W., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0126 · Cited by 170
Matikainen, N., Söderlund, S., Björnson, E., Pietiläinen, K., Hakkarainen, A., Lundbom, N., Taskinen, M., & Borén, J. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13487 · Cited by 129
Self-citationApolipoprotein C-III and hepatic triglyceride-rich lipoprotein production
Yao, Z., & Wang, Y. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328352dc70 · Cited by 100
Modification of lipoprotein metabolism and function driving atherogenesis in diabetes
Luciani, L., Pedrelli, M., & Parini, P. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117545 · Cited by 72
Protein biomarkers for the prediction of cardiovascular disease in type 2 diabetes
on behalf of the SUMMIT Investigators, Looker, H. C., Colombo, M., Agakov, F., Zeller, T., Groop, L., Thorand, B., Palmer, C. N., Hamsten, A., de Faire, U., et al. (2015) · Diabetologia · doi:10.1007/s00125-015-3535-6 · Cited by 66
Ginsberg (2011) · doi:10.1161/atvbaha.110.221846 · Cited by 64
Role of apolipoprotein C-III overproduction in diabetic dyslipidaemia
Adiels, M., Taskinen, M., Björnson, E., Andersson, L., Matikainen, N., Söderlund, S., Kahri, J., Hakkarainen, A., Lundbom, N., Sihlbom, C., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13744 · Cited by 55
Self-citationApolipoprotein status in type 2 diabetes mellitus and its complications
Zhang, P., Gao, J., Pu, C., & Zhang, Y. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.7831 · Cited by 55
“Glucose induces apoC-III transcription, which may represent a mechanism that links hyperglycaemia, hypertriglyceridaemia and CVD in patients with T2DM; this process is inhibited by treatment with agonists of farnesoid X receptor and peroxisome proliferator-activated receptor-α (35).”
Effects of liraglutide on the metabolism of triglyceride-rich lipoproteins in type 2 diabetes
Taskinen, M., Björnson, E., Matikainen, N., Söderlund, S., Pietiläinen, K. H., Ainola, M., Hakkarainen, A., Lundbom, N., Fuchs, J., Thorsell, A., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14328 · Cited by 40
Self-citationPan, B.-Y., Chen, C.-S., Chen, F.-Y., & Shen, M.-Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312759 · Cited by 19
Metadata
- Authors
- Caron, S., Verrijken, A., Mertens, I., Samanez, C. H., Mautino, G., Haas, J. T., Duran-Sandoval, D., Prawitt, J., Francque, S., Vallez, E., Muhr-Tailleux, A., Berard, I., Kuipers, F., Kuivenhoven, J. A., Biddinger, S. B., Taskinen, M.-R., Van Gaal, L., & Staels, B.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2011-03
- Volume
- 31
- Issue
- 3
- Pages
- 513-519
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2112284378
- Cited by
- 162
- References
- 11
- FWCI
- 3.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.